Feiskhanova LI

Language: English
References: 8
Page: 76-78
PDF size: 145.87 Kb.

ABSTRACT

Background. Rheumatoid arthritis (RA) is often accompanied by anemia. The aim of this study was to determine the effect of anemia on the structural-geometric state of the heart in patients with rheumatoid arthritis. Material and methods. 154 patients suffering from RA were involved in our research. Out of them, 37 were diagnosed with mild or moderate anemia (1st group), and 117 did not have systemic manifestations of RA (2nd group). By echocardiography were calculated left ventricular myocardial mass index, relative wall thickness of the left ventricle, left ventricle ejection fraction, left ventricular end-diastolic diameter, and E/a parameters of mitral and tricuspid valves. Results. In correlation analysis in the 1st group we found a direct correlation between age and the left ventricular myocardial mass index (r=0.62, p‹0.0005), between age and the left ventricular end-diastolic diameter (r=0.37, p‹0.05). We also found a negative correlation between age and E/a parameter of mitral valve (r=-0.71, p<0.00001), between DAS-28 index and E/a parameter of tricuspid valve (r=-0.43, p‹0.05), between anti-MCV level and the E/a parameter of mitral valve (r=-0.9, p‹0.05). In the group of patients without systemic manifestations, we found a direct correlation between age and the left ventricular myocardium mass index (r=0.46, p‹0.0001), between age and relative wall thickness (r=0.43, p‹0. 0005), and also the negative correlation between age and the E/a parameter of the mitral valve (r=-0.55, p‹0.00001; r= - 0.27, p‹0.05 respectively). Conclusions. Regardless of the anemia presence in patients with rheumatoid arthritis, the structural-geometric changes of the heart depend on age, namely, left ventricular myocardium mass index increases, and the diastolic function of the left ventricle is impaired. At the same time, in patients with anemia, increase of the activity of RA entails a worsening in the diastolic function of the right ventricle, and increase of anti-MCV level correlates with diastolic dysfunction of the left ventricle.

REFERENCES

1. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safetyof new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-62.

2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for themanagement of patients with atrial fibrillation: executive summary: a report of theAmerican College of Cardiology/American Heart Association Task Force on practiceguidelines and the Heart Rhythm Society. Circulation 2014;130:2071-104.

3. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the managementof atrial fibrillation developed in collaboration with EACTS. Eur Heart J2016;37:2893-962.

4. Savarese G, Giugliano RP, Rosano GM, et al. Efficacy and safety of novel oralanticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis.JACC Heart failure 2016;4:870-80.

5. The ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulationfor atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan forprevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet2006;367:1903-12.

6. Yang X, Li Z, Zhao X, Wang C, Liu L, Wang C, et al. Use of Warfarin at DischargeAmong Acute Ischemic Stroke Patients With Nonvalvular Atrial Fibrillation inChina. Stroke 2016;47:464-70.

7. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and managementin atrial fibrillation patients. Executive Summary of a Position Document from theEuropean Heart Rhythm Association [EHRA], endorsed by the European Societyof Cardiology [ESC] Working Group on Thrombosis. Thrombosis and haemostasis2011;106:997-1011.

8. Burgess S, Crown N, Louzada ML, et al. Clinical performance of bleeding riskscores for predicting major and clinically relevant non-major bleeding events inpatients receiving warfarin. J Thromb Haemost 2013;11:1647-54.